Loading…
On Friday (9/9/2022) the Food and Drug Supervisory Agency (BPOM) issued a distribution allow for the dengue vaccine named Qdenga. / Photo: illustration / freepik.com
Qdenga vaccine is a vaccine with an indication to prevent dengue disease triggered by the dengue virus.
The Qdenga vaccine can be provided to men and women between the ages of 6 and 45. This vaccine is made by IDT Biologika GmbHg Germany, and issued and registered on behalf of Takeda GmbH Germany.
Study also: Queen Elizabeth II dies, this is the key of her longevity up to 96 years
“This vaccine is the second dengue vaccine accepted for distribution by BPOM soon after Dengvaxia (registered underneath the identify of PT Aventis Pharma),” he defined. BPOM in its formal statement, Friday (9/9/2022).
Qdenga vaccine is a form of Reside Attenuated Tetravalent Dengue (TDV) vaccine consisting of 4 strains of dengue virus, i.e. the attenuated pressure of dengue serotype 2 (TDV-2), recombinant dengue serotype 2/1 (TDV -1), recombinant dengue serotype 2 pressure / 3 (TDV-3) and recombinant dengue serotype 2/4 (TDV-4) pressure.
The TDV-2 strain vaccine is composed of attenuated Dengue virus variety 2 (attenuated). In the meantime, the attenuated vaccine strains of serotypes 1, 3 and 4 ended up engineered by changing the pre-membrane (prM) and envelope (E) gene constructions of TDV-2 with the prM and E genes for the dengue virus. type 1, dengue virus form 3, and strains of dengue dengue virus variety 4.
How powerful is the Qdenga vaccine?
The efficacy of the Qdenga vaccine is demonstrated by data from Phase 3 clinical trials and is supported by immunogenicity data from Stage 3 and 2 scientific trials.
“This vaccine displays good efficacy in seropositive people (who have antibodies to the dengue virus) and in seronegative people (who do not still have antibodies to the dengue virus),” BPOM mentioned.
–
